Astaxanthin
ApprovedSmall molecule
Astaxanthin is one of 101 small molecule programs targeting Pneumonia. It is currently in Approved.
3
Indications
6
Total Trials
1
Active Trials
100
Competitors
Pipeline
Status by Indication[3][1]
Indication
Competition
Competitive Landscape
778 competitors in Osteoarthritis
#DrugCompanyPhaseTrials
1Astaxanthin
SSheba Medical Center
Approved
Epidiolex
Jazz PharmaceuticalsPreclinical
Ilaris
NovartisPreclinical
Toradol
RochePreclinical
Voltaren
CCerimon Pharmaceuticals
Preclinical
Platelet Rich Plasma
ZZagazig University
Preclinical
Bayer Aspirin
BayerPreclinical
Glucophage
Boehringer IngelheimPreclinical
Precedex
MMcNeil Consumer & Specialty Pharmaceuticals, a Division of McNeil-PPC, Inc.
Preclinical
Protonix
WWyeth-Lederle Vaccines
Preclinical
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Clinical
Trials by Indication[1]
Osteoarthritis2 trials
Effect of Astaxanthin in Moderate to Severe Knee Osteoarthritis
Completed·—·Phase 2·NCT05437601·80 enrolled
Humans1 trial
Diabetic Neuropathy1 trial
The Benefits of Astaxanthin as Add on Therapy in the Management of Painful Diabetic Neuropathy Patient
Unknown status·—·Phase 2/3·NCT04689984·60 enrolled
Pneumonia1 trial
Treatment1 trial
ROAR-DIGAP: A Widely Inclusive, Largely Virtual Pilot Trial Utilizing DIGAP (Deep Integrated Genomics Analysis Platform) To Personalize Treatments
Completed·—·Phase 2·NCT06429059·50 enrolled
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for Astaxanthin. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details
Drug Info
Quick Facts
- Modality
- Small molecule[2]
- Highest Phase
- Approved[1]
- Company
- SSheba Medical Center